Actively Recruiting

Phase 1
Age: 18Years - 55Years
All Genders
Healthy Volunteers
NCT07534592

A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants

Led by AstraZeneca · Updated on 2026-05-12

40

Participants Needed

2

Research Sites

22 weeks

Total Duration

On this page

Sponsors

A

AstraZeneca

Lead Sponsor

P

Parexel

Collaborating Sponsor

AI-Summary

What this Trial Is About

The study has 2 groups, one each focusing on co-administration of elecoglipron and atorvastatin or rosuvastatin to assess the pharmacokinetics (PK) of atorvastatin in healthy participants.

CONDITIONS

Official Title

A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants

Who Can Participate

Age: 18Years - 55Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • All females must have a negative pregnancy test at screening and admission
  • Females of childbearing potential must not be breastfeeding and must use effective contraception if sexually active
  • Females not of childbearing potential must be postmenopausal or surgically sterilized by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy
  • Sexually active fertile male participants with partners of childbearing potential must use contraception
Not Eligible

You will not qualify if you...

  • History of any clinically important disease or disorder
  • Cardiovascular diseases, neuromuscular or neurogenic disease, type 1 or type 2 diabetes mellitus, HIV infection, or uncontrolled thyroid disease
  • History of acute pancreatitis or gastrointestinal conditions affecting drug absorption or metabolism
  • Clinically significant inflammatory bowel disease, gastroparesis, severe disease, or surgery affecting the upper gastrointestinal tract
  • Any important illness, surgery, or trauma within 4 weeks before study treatment
  • Clinically important abnormalities in lab tests or vital signs
  • Abnormalities in resting 12-lead electrocardiogram
  • History of severe allergy or ongoing allergy to drugs similar to elecoglipron or paracetamol
  • Previously received elecoglipron in last 6 months or statin treatment within 4 weeks prior to study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Research Site

Glendale, California, United States, 91206

Not Yet Recruiting

2

Research Site

Brooklyn, Maryland, United States, 21225

Actively Recruiting

Loading map...

Research Team

A

AstraZeneca Clinical Study Information Center

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SEQUENTIAL

Primary Purpose

TREATMENT

Number of Arms

11

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here